6200.0000 -1.00 (-0.02%)
NSE Jun 05, 2026 09:19 AM
Volume: 334
 

6200.00
-0.02%
ICICI Direct
Q4FY26 - Strong revenue growth and margin improvement - Revenues were up ~20% YoY to 370 crore driven by power brands of Neurobion Forte (Multivitamins), Livogen (Iron compounds), and Polybion (Vitamin B complex) but pulled down by de-growth in Evion (Vitamin E) and Nasivion (nasal decongestant). EBITDA grew ~67% YoY to ~136 crore and margins increased 1058 bps YoY to 36.6% mainly due to 31% increase in...
Number of FII/FPI investors decreased from 151 to 144 in Mar 2026 qtr
More from Procter & Gamble Health Ltd.
Recommended